Rallybio Corporation is a biotechnology company focused on discovering and developing innovative therapies for rare and life-threatening diseases
The company specializes in creating breakthrough treatments that target the underlying causes of these conditions, aiming to significantly improve patient outcomes. Rallybio's research and development efforts are centered around advancing its robust pipeline of candidates designed to address critical unmet medical needs within the rare disease community. Through strategic partnerships and a commitment to scientific excellence, Rallybio is positioned to make a meaningful impact on patients' lives.
Shares of NextPlat Corp (NASDAQNXPL) rose sharply in today’s pre-market trading after the company reported consolidated 2023 revenues of $37.8 million, up 222% year over year
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite surging more than 250 points on Thursday. The Dow traded up 0.18% to 38,532.50 while the NASDAQ rose 1.63% to 16,433.83. The S&P 500 also rose, gaining, 0.83% to 5,203.26.
U.S. stocks were mixed, with the Dow Jones index falling over 50 points on Thursday. Shares of Enliven Therapeutics, Inc. (NASDAQELVN) rose sharply during Thursday’s session.
U.S. stocks traded mostly higher this morning, following the release of PPI data. Following the market opening Thursday, the Dow traded up 0.03% to 38,472.80 while the NASDAQ rose 0.40% to 16,234.94. The S&P 500 also rose, gaining, 0.17% to 5,169.21.
Rallybio partners with Johnson & Johnson to develop therapies targeting fetal and neonatal alloimmune thrombocytopenia, receiving $6.6 million investment. Phase 2 study for RLYB212 set for 2024.
Shares of Rallybio Corporation (NASDAQRLYB) rose sharply in today’s pre-market trading after the company announced a collaboration with Johnson & Johnson to advance therapeutics for pregnant individuals at risk of FNAIT.
